The absence of mutations in UBXN2A and Rictor genes increases the potential therapeutic efficacy of VTD as a UBXN2A enhancer and a potent Rictor suppressor in patients with CRC in early- and late-onset as well as the metastatic stage of CRC. This evidence concerns the gene UBXN2A and colorectal carcinoma.